Drug
Aro Ang3
Aro Ang3: highest development phase Phase 1, developed by Arrowhead Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARO-ANG3 NCT03747224 | Phase 1 | Dyslipidemias |
Latest
No recent events.
Follow Aro Ang3 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.